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The  pro-inﬂammatory  cytokine  interleukin-17A  (IL-17)  has  been  the subject  of  research  by  many  groups
worldwide.  IL-17  expression  is often  associated  with a speciﬁc  subset  of  CD4+  T cells (the  so-called  Th17
cells);  however  various  other  immune  cell  subsets  can  also  synthesise  and express  IL-17,  including  CD8+  T
cells. Here  we  review  recent  data  regarding  the presence  of IL-17+  CD8+  T cells  (also  known  as  Tc17  cells)
in  human  inﬂammatory  disease,  discuss  current  knowledge  regarding  the  culture  conditions  required
for  the  differentiation  of  these  cells  in humans  and  mice,  and  describe  key  phenotypic  and  functional
features.  Collectively,  this  information  may  shed  light  on the  potential  pathogenic  role  that  IL-17+ CD8+
T  cells  may  play  in human  inﬂammatory  disease.
©  2016  The  Authors.  Published  by Elsevier  B.V.  on  behalf  of European  Federation  of  Immunological
Societies.  This  is an  open  access  article  under  the  CC  BY  license  (http://creativecommons.org/licenses/
by/4.0/).
. Introduction
Since its discovery in 1993 [1], the pro-inﬂammatory cytokine interleukin (IL)-17A (in this review generally referred to as IL-17) has
een the subject of intense research. The interest in this cytokine increased considerably when it was  found to be produced by a speciﬁc
ubset of CD4+ T cells, the so-called Th17 cells. However, it is well established that other immune cell subsets can also synthesise and
xpress IL-17, including CD8+ T cells. In this review, we summarise current data regarding the presence of IL-17+ CD8+ T cells in human
nﬂammatory disease, discuss the differentiation and polarisation protocols reported to induce these cells in humans and mice, and describe
urrent knowledge regarding their phenotype and function. We  also discuss how these cells may  contribute to immunopathology in human
nﬂammatory diseases.
. Presence of IL-17+ CD8+ T cells in human inﬂammatory disease
The presence of IL-17-expressing CD8+ T cells (also referred to as Tc17 cells) has been described in several human inﬂammatory diseases.
n early study reported the presence of IL-17 mRNA in CD8+ T cell clones derived from psoriatic lesional skin [2]. Later studies using ﬂow
ytometry, demonstrated that psoriatic skin plaques contain increased numbers [3] or proportions of IL-17+ CD8+ T cells [4–6], whilst
his was not observed in control skin samples. Our own lab showed that synovial ﬂuid from the inﬂamed joints of patients with psoriatic
rthritis, but not rheumatoid arthritis, contains increased frequencies of IL-17+ CD8+ T cells compared to matched peripheral blood [7].
n active lesions in brain tissue from patients with multiple sclerosis, IL-17 expression was detected in both CD8+ and CD4+ T cells with
qual distribution, and both cell types were present at higher levels compared to inactive lesions [8]. In children with new onset type I
iabetes, an increased percentage of IL-17+ cells within peripheral blood CD8+ and CD4+ T cell populations was  found following 3 days of
n vitro stimulation compared to age-matched healthy controls [9]. IL-17+ CD8+ T cells were found to be enriched in the liver of patients
ith chronic hepatitis C virus (HCV) infection or nonalcoholic steatohepatitis [10] and in the pleural effusion of tuberculosis patients [11]
Abbreviations: EAE, experimental autoimmune encephalomyelitis; HCV, hepatitis C virus; IRF, interferon regulatory factor; ROR, retinoic acid receptor-related orphan
eceptor gamma.
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ompared to peripheral blood. Finally, using immunoﬂuorescence staining, CD8+ T cells expressing IL-17A and IL-17F were detected in
ronchoscopic biopsies from the subsegmental bronchi of patients with chronic obstructive pulmonary disease, at percentages similar to
D4+ T cells [12]. Together, these data demonstrate that IL-17+ CD8+ T cells are present in inﬂamed tissue in various human inﬂammatory
iseases suggesting these cells may  contribute to immune pathology.
. IL-17+ CD8+ T cell differentiation and polarisation in humans and mice
It is well established that transforming growth factor (TGF)-,  IL-6, IL-1, IL-21 and IL-23 can promote IL-17+ CD4+ T cell differentiation
n humans [13–16] and mice [17–20]. Since IL-17+ CD8+ T cells have a similar cytokine proﬁle to IL-17+ CD4+ T cells, this provides a
ationale for applying IL-17+ CD4+ T cell polarising conditions to induce or expand IL-17+ CD8+ T cells. Table 1 summarises the in vitro
ulture conditions reported thus far to expand human or mouse IL-17+ CD8+ T cells and IL-17+ interferon (IFN)-+  dual producing CD8+
 cells. A limited number of human IL-17+ CD8+ T cell differentiation studies are published to date compared to those in mice. One study
eported that human IL-17+ CD8+ T cells were induced upon culture of naïve CD8+ T cells with recombinant TGF-, IL-6, IL-1, IL-23 and
-IFN- mAb  for 5 days, followed by IL-2 addition for a further 4 days [21]. However, a representative ﬁgure showed 0.11% of IL-17+ CD8+
 cells indicating that only a limited percentage of these cells was  induced. Another protocol involved culturing human bulk CD8+ T cells
ith TGF- and IL-6 for 3 days [22]. IL-17+ CD8+ T cell induction frequencies were not reported, but low IL-17 levels were detected by
LISA.
More detailed information stems from mouse studies, in which TGF- and IL-6 have been used to drive IL-17+ CD8+ T cell differentiation
rom CD8+ T cells [23–29], leading to frequencies ranging from 19%–64% (Table 1). TGF- decreases IFN- production, while reducing
ytolytic activity and expression of the cytolytic marker granzyme B within in vitro cultured CD8+ T cells [24,25]. TGF- also inhibits CD8+
 cell proliferation and division, but in concert with IL-6, these TGF--mediated actions are opposed while maintaining reduced cytolytic
ctivity, a characteristic of IL-17+ CD8+ T cells [25]. A role for IL-6 in IL-17+ CD8+ T cell induction was also shown in mice in vivo, since after
llogeneic stem cell transplantation IL-6R blockade reduced IL-17+ CD8+ T cell frequencies [30]. In contrast to IL-6, the effects of TGF-
ay vary between in vitro and in vivo conditions. TGF- removal from the IL-17+ CD8+ T cell differentiation cocktail containing IL-1,
L-2, IL-6, IL-21, IL-23, -IL-4 and -IFN- mAbs led to a strong reduction in IL-17+ CD8+ T cell percentages in vitro [23]. However, in vivo
GF- neutralisation in mice did not considerably affect IL-17+ CD8+ T cell frequencies [30]. Furthermore, TGF-RIIDN mice with impaired
GF- signalling still exhibited IL-17+ CD8+ T cell differentiation, whilst IL-17+ CD4+ T cell differentiation was inhibited [31], suggesting
hat TGF- may  not be critical for in vivo IL-17+ CD8+ T cell differentiation, and that cytokines required for IL-17 induction in CD4+ versus
D8+ T cells may  differ.
IL-21 has also been shown to be important for IL-17+ CD8+ T cell differentiation in mouse cells, either as part of a cytokine cocktail
TGF-, IL-6, IL-1, IL-2, IL-21, IL-23, -IL-4 and -IFN- mAb) [23] or in combination with TGF- [32]. Increased Il21 mRNA expression
as observed in mouse CD8+ T cells cultured with TGF- and IL-21, with TGF- and IL-6, or with IL-21 alone [24]. IL-21 production by
L-17+ CD8+ T cells may  promote a positive feedback loop to expand IL-17+ CD8+ T cells further, an autocrine mechanism reported in IL-17+
D4+ T cells [20,33]. Human stimulated IL-17+ CD8+ T cells from psoriatic lesions express IL-21 [5], however it remains to be established
hether IL-21 is important for human IL-17+ CD8+ T cell differentiation.
IL-23 is often used to expand human IL-17+ CD4+ T cells [14,15]. IL-23 addition to hapten-primed mouse CD8+ T cell and dendritic cell
o-cultures induced IL-17 production [34], yet IL-23 alone only slightly induced Il17a expression in mouse naïve CD8+ T cell cultures [27].
hus, IL-23 may  maintain the IL-17+ CD8+ T cell phenotype rather than drive differentiation, similar to its role in IL-17+ CD4+ T cells [35]. In
umans, a role for IL-23 in IL-17+ CD8+ T cell differentiation is not yet elucidated, however one study revealed that heterozygous carriers
f the R381Q IL23R variant exhibited reduced IL-17+ CD8+ T cell frequencies compared to carriers of the common variant [36], indicating
 potential role of IL-23 in human IL-17+ CD8+ T cell development. IFN- neutralisation expanded mouse IL-17+ CD8+ T cells in vitro
23,26,32] and -IFN- mAb  removal from the polarising cocktail also containing IL-1, IL-2, IL-6, IL-21, IL-23, TGF- and -IL-4 mAb,
educed IL-17+ CD8+ T cell frequencies [23]. These data indicate that IFN- reduces IL-17+ CD8+ T cell expansion, as seen in mouse IL-17+
D4+ T cell studies [37]. In support of this, Type I IFN signalling-deﬁcient mice (used to inhibit IFN-+ CD8+ T cell induction) treated with
eutralising IFN- Abs showed higher IL-17+ CD8+ T cell levels in vivo, as compared to wild type mice [27]. IL-17+ CD8+ T cell frequencies
ere also expanded in vivo when allogeneic mice were injected with -IFN- mAb  7 days post-stem cell transplant [30]. Additionally,
igher IL-17+ CD8+ T cell frequencies were reported in IFN--deﬁcient OT-I mice compared to wild-type mice [23], further indicating that
FN- inhibition in vivo enhances IL-17 production by CD8+ T cells in mice. IFN- was neutralised in one in vitro human IL-17+ CD8+ T cell
ifferentiation study [21], however further investigations are required to establish its exact role in the human context.
Collectively, the ﬁndings reported thus far indicate that similarities exist between the culture conditions used for mouse IL-17+ CD8+
nd IL-17+ CD4+ T cell differentiation. However, there are still signiﬁcant gaps in our knowledge regarding the exact conditions required
or human IL-17+ CD8+ T cell induction or expansion. It will be important to address these gaps in future, given the accumulating evidence
f the presence of these cells in human inﬂammatory disease, which warrants detailed investigation of their function.
. Phenotype of IL-17+ CD8+ T cells in humans and mice
To date, phenotypic proﬁling of human IL-17+ CD8+ T cells has been limited at both protein and molecular level, although some char-
cterisation has been performed. Furthermore, variation in the inﬂammatory sites from which cells are sourced combined with disparity
etween in vitro induction or expansion protocols makes comparison of individual studies challenging. Despite these challenges some phe-
otypic features have been described for human IL-17+ CD8+ T cells including surface marker, cytokine and transcription factor expression.
 summary of current mouse and human IL-17+ CD8+ T cell phenotype data is shown in Fig. 1. Several of these features are shared with
L-17+ CD4+ T (Th17) cells, indicating some similarities between these cell types which may  give an insight into the functional potential
f IL-17+ CD8+ T cells
The most deﬁnitive feature of human IL-17+ CD8+ T cells is their ability to produce the pro-inﬂammatory cytokine IL-17A (IL-17) but
oncurrent expression of several other cytokines has been shown. The most well-described of these is the pro-inﬂammatory cytokine IFN-,
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Table 1
Summary of reported culture conditions used to induce or expand human and mouse IL-17+ CD8+ T cells in vitro.
Species CD8+ T cell type Culture
conditions
IL-17+ CD8+ T cell yield IL-17+ IFN-+ CD8+ T cell yield Ref.
Human Naïve CD8+ T
cells + -CD3 + -CD28
TGF-, IL-6,
IL-1,  IL-23
and -IFN-
(5 days), IL-2
(further
4  days).
0.11% of naïve CD8+ T cells
expressed IL-17
(representative ﬁgure using
intracellular staining)
N/A [21]
Bulk CD8+ T
cells + -CD3 + -CD28
TGF- and IL-6
(3 days)
No report on % IL-17+ CD8+ T
cells. 25 pg/ml IL-17A secretion
by ELISA (n = 3)
N/A [22]
Mouse Lymph node hapten-primed
CD8+ T cells + bone-marrow
derived dendritic cells
IL-23 (2 days) No report on % IL-17+ CD8+ T
cells. 1.4 ng/ml IL-17A
secretion by ELISA (n = 3)
N/A [34]
Mixed lymphocyte cultures
(splenocytes)
TGF- and IL-6
(5 days)
32% of CD8+ cells expressed
IL-17 (representative ﬁgure
using intracellular staining,
reported to be reproducible in
n = 3)
N/A [25]
Naïve CD8+ T cells (spleen or
lymph
node) + Ag + -CD3 + -CD28
TGF- and IL-6
or TGF- and
IL-21 (3 days)
TGF- + IL-6: 29% of CD8+ T
cells expressed IL-17
TGF- + IL-6: 1.2% CD8+ T cells
expressed IL-17 and IFN-
[24]
TGF- + IL-21: 24% of CD8+ T
cells expressed IL-17
(representative ﬁgure using
intracellular staining)
TGF- + IL-21: 0.7% CD8+ T
cells expressed IL-17 and IFN-
(representative ﬁgure using
intracellular staining)
OT-I  CD8+ T cells stimulated
with OVA-derived peptide
SIINFEKL-pulsed B blasts
TGF-, IL-6,
IL-1,  IL-2,
IL-21, IL-23,
-IL-4 and
-IFN-
(4 days)
54% of CD8+ T cells expressed
IL-17 (representative ﬁgure
using intracellular staining)
0.5% of CD8+ T cells expressed
IL-17 and IFN-
(representative ﬁgure using
intracellular staining)
[23]
Naïve CD8+ T cells
(splenocytes) activated with
cognate peptide and irradiated
antigen-presenting cells (APCs)
TGF-, IL-6,
IL-1,  IL-23,
-IL-4 and
-IFN-
(2 days),
followed by a
3 day rest.
39% (mean) of CD8+ T cells
expressed IL-17 (n = 4)
4% (mean) of CD8+ T cells
expressed IL-17 and IFN-
(n = 4)
[26]
Bulk CD8+ T cells (splenocytes)
stimulated with OVA-peptide +
IL-12/IL-23p40 deﬁcient APCs
TGF- and IL-6
(5 days)
23% (mean) of CD8+ T cells
expressed IL-17 (n = 4)
N/A [27]
Bulk CD8+ T cells (splenocytes)
+  -CD3 + -CD28
Combinations
of cytokines:
TGF-, IL-6,
IL-21, IL-23,
IL-1, TNF-,
IL-2, -IFN-,
-IL-2 (3 days)
TGF- + IL-6: 45% of CD8+ T
cells expressed IL-17 TGF-,
IL-6, -IFN-, -IL-2: 64% of
IL-17-expressed CD8+ T cells
(based on representative
ﬁgures using intracellular
staining)
TGF- + IL-6: 10% of CD8+ T
cells expressed IL-17 and IFN-
TGF-,  IL-6, IL-1: 18% of CD8+
T  cells expressed IL-17 and
IFN- (based on representative
ﬁgures using intracellular
staining)
[32]
Bulk CD8+ T
cells + -CD3 + -CD28 and
CD8+-depleted irradiated
splenocytes
TGF- and IL-6
(5 days)
57% of CD8+ T cells expressed
IL-17 (based on representative
ﬁgures using intracellular
staining)
16% of CD8+ T cells expressed
IL-17 and IFN- (based on
representative ﬁgures using
intracellular staining)
[28]
Bulk CD8+ T cells +
-CD3 + -CD28
TGF- and IL-6
(3 days)
TGF- + IL-6: 19% of CD8+ T
cells expressed IL-17 (based on
representative ﬁgures using
intracellular staining)
N/A [29]
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Table 1 summarises data from existing literature regarding in vitro induction protocols of mouse and human IL-17+ CD8+ T cells. The table lists the cell type, TCR stimulation
nd  co-stimulation methods, recombinant cytokines and blocking mAbs used, culture duration and yield of both IL-17+ CD8+ T cells and IL-17+ IFN-+ dual producing CD8+
 cells.
hich is found to be co-expressed with IL-17 in cultured IL-17+ CD8+ T cells from healthy blood [21] and psoriatic plaques [5]. Furthermore
L-17/IFN- dual producers derived from the liver tissue of patients with hepatitis C infection produced higher levels of IFN- than IFN-+
D8+ T (Tc1) cells, indicating these cells may  represent a population with higher pro-inﬂammatory potential [10]. In addition, several other
ro-inﬂammatory cytokines such as tumour necrosis factor alpha (TNF-), IL-21 and IL-22 have been shown to be co-expressed with IL-17
y human and mouse IL-17+ CD8+ T cells [5,10,24,26]. Granulocyte macrophage colony stimulating factor (GM-CSF) co-expression has also
een reported, at least in mouse [30]. Moreover, evidence for lack of co-expression of the anti-inﬂammatory cytokine IL-10 by IL-17+ CD8+
 cells in mice supports classiﬁcation of IL-17+ CD8+ T cells as pro-inﬂammatory [30]. At the molecular level, studies into the phenotype of
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Fig. 1. Phenotype of mouse and human IL-17+ CD8+ T cells.
(A) Mouse IL-17+ CD8+ T cells express CCR6 and IL-23R [24,26], and can produce the pro-inﬂammatory cytokines IL-17A, IFN-, TNF-, IL-21, IL-22 and GM-CSF [24,26,29,30].
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Cranscription factors expressed by mouse IL-17+ CD8+ T cells include RORt, ROR, STAT3 and IRF4 [24,26,29].
B)  Human IL-17+ CD8+ T cells express CCR6, CD161, CCR5 and IL-23R [5,7,10,21] and can produce IL-17A, IFN-, TNF-, IL-21 and IL-22 [5,21]. Expression of the transcription
actor RORt has been conﬁrmed in human IL-17+CD8+ cells [5].
uman IL-17+ CD8+ T cells have been restricted, with only one study showing that RORC (encoding retinoic acid receptor-related orphan
eceptor gamma; RORt) gene expression was increased in psoriatic skin IL-17+ CD8+ T cells, compared to IL-17- CD8+ T cells, which in
ontrast expressed higher expression of TBX21 (encoding T-Bet) [5]. This is supported by data from mouse models where Rorc has been
hown to be expressed at a high level in spleen and lymph node (LN) derived IL-17+ CD8+ T cells differentiated in vitro [24,26,29]. RORt
as been extensively implicated in the development and function of IL-17+ CD4+ T cells, and these data suggest that IL-17+ CD8+ T cell
henotype and function may  be deﬁned by a similar mechanism.
In the above studies, Rorc up-regulation in IL-17+ CD8+ T cells was accompanied by an increase in expression of another ROR subfamily
omologue, Rora (encoding retinoic acid receptor-related orphan receptor alpha) plus a reduction in Eomes (encoding Eomesodermin)
24,26,29,30]. Other markers of CD8+ T cell effector cells such as Tbx21 and Gata3 were reduced in these cells with the exception of one
tudy in which CD8+YFP+ cells from IL-17A-YFP+ reporter mice were shown to have notable Tbx21 expression, although this was performed
ver an extensive time course and may  be linked to the plasticity of IL-17+ CD8+ T cells to produce IFN- over time [30]. Furthermore, CD8+
 cells from Tbx21 and Eomes double knockout mice have higher IL-17A expression compared to wild type cells [38]. Overall these ﬁndings
ndicate that the absence of Tbx21 and Eomes expression plus up-regulation of Rora and Rorc currently represent a reliable molecular
haracterisation of IL-17+ CD8+ T cells, at least in mice.
Additional transcription factors have been implicated in the induction of IL-17+ CD8+ T cells including signal transducer and activator
f transcription 3 (STAT3), interferon regulator factor 3 (IRF3) and interferon regulatory factor 4 (IRF4), at least in mice. Knockdown of
TAT3 by siRNA in spleen or lymph node-derived CD8+ T cells resulted in a reduction of IL-17+ CD8+ T cell frequencies under IL-17+ CD8+ T
ell differentiation conditions [24]. A similar reduction in IL-17+ CD8+ T cells was seen under these conditions in an IRF4 knockout mouse,
nd this phenotype was  partially reversed upon overexpression of RORt in IRF4−/− cells [29]. In contrast, CD8+ T cells derived from the
pleen or lymph nodes of IRF3 knockout mice showed increased IL-17A production and upregulated Il23r gene expression under IL-17+
D8+ T cell differentiation conditions. Interestingly, a direct interaction between IRF3 and RORt transcription factors was identiﬁed in
he cytoplasm under IL-17+ CD8+ T cell differentiation conditions indicating that IRF3 may  act as a negative regulator of IL-17 induction
n IL-17+ CD8+ T cells by antagonistically binding RORyt and therefore reducing downstream interactions [39].
At the protein level, human IL-17+ CD8+ T cells express several surface markers, although as yet no markers have been deﬁned that
re exclusively expressed on these cells. The majority of cultured IL-17+ CD8+ T cells isolated from active psoriatic plaques were found to
xpress CD161 [5]. Furthermore, CD8+ T cells isolated from liver biopsies of patients with chronic HCV infection were found to co-express
D161 and IL-17 after ex vivo stimulation [10], which was also observed ex vivo in stimulated CD3+ CD4- IL-17+ T cells from the joints of
atients with psoriatic arthritis [7]. CD161 has been shown to be a marker of CD4+ IL-17+ T lymphocytes, however it does not represent a
eﬁnitive marker for IL-17+ T cells as not all CD161+ cells produce IL-17 [40].
IL-17+ CD8+ T cells have also been shown to express certain cytokine and chemokine receptors, highlighting their potential to respond
o inﬂammatory mediators in the surrounding environment. When CD8+ T cells from healthy blood were sorted based on expression of
D8 and various chemokine receptors followed by PMA  and ionomycin stimulation for 6 h, CCR5high and CCR6+ populations were found to
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ontain increased frequencies of IL-17+ CD8+ T cells compared to CCR4+ and CCR7+ cells [21]. Additionally, stimulated CD8+ T cells from
soriatic plaques, pleural effusions from patients with tuberculosis and healthy blood have been shown to co-express both IL-17 and CCR6
11,41]. Although these data do not conﬁrm that all IL-17+ CD8+ T cells express CCR6, data from an IL-17A-YFP reporter mouse have shown
n increase in Ccr6 gene expression in YFP+CD8+ T cells indicating the expression of both CCR6 and IL-17A production is correlated to some
xtent [30]. With regards to cytokine receptor expression, IL-23 receptor (IL-23R) has been shown to be expressed on CCR6+ CD8+ T cells
ultured under IL-17+ CD8+ T cell induction conditions [5]. This is further supported by an increase in IL-23R expression in IL-17+ CD8+ T
ells derived from experimental autoimmune encephalomyelitis (EAE) mice [24].
Not unexpectedly, human IL-17+ CD8+ T cells appear to have a memory phenotype since the highest proportion of IL-17+ CD8+ T cells
ound in healthy blood are either CD27+CD28+CD45RA- or CD27-CD28+CD45RA- cells, and cultured IL-17+ CD8+ T cells from psoriatic skin
xpress CD45RO [5,11,21].
. Function and pathogenicity of IL-17+ CD8+ T cells
.1. Production of cytokines
IL-17+ CD8+ T cells are deﬁned by their ability to produce the pro-inﬂammatory cytokine IL-17A. These cells often also co-express
ne or several other cytokines including IFN-, TNF-, IL-21, IL-22 and/or GM-CSF (the latter has not yet been reported in humans)
5,10,21,26,30]. IL-17 can induce production of inﬂammatory mediators such as TNF-, IL-6, IL-8 and chemokine (C-X-C motif) ligand 1
CXCL1) by monocytes and ﬁbroblasts, induce production of matrix metalloproteinases and promote osteoclastogenesis [42]. IFN-, most
requently co-expressed in IL-17+ CD8+ T cells [5,10,21], is a pro-inﬂammatory cytokine typically expressed by some CD4+ and CD8+ T cells
s well as some Natural Killer (NK) cells. IFN- is crucial for the induction of type I immunity and as described previously, IL-17A+ IFN-+
D8+ T cells were found to produce higher levels of IFN- than IFN- single-producing T cells [10]. TNF- is also expressed by a broad
ange of immune cell types during inﬂammation and is capable of acting on a number of cell types including synergistically with IL-17 to
romote activation of synovial ﬁbroblasts and keratinocytes in the skin and joint of patients with RA and psoriasis [43,44]. IL-21 is a known
river of IL-17+ CD4+ T cell differentiation and is required for IL-17+ CD4+ T cell mediated pathogenesis in some models of inﬂammation
n mice [33]; this cytokine may  have a similar role in IL-17+ CD8+ T cell differentiation, though this is still to be fully investigated. IL-22
s produced by T cells and NK cells and has been shown to mediate keratinocyte differentiation and proliferation in psoriatic skin [45,46].
M-CSF is a potent driver of inﬂammation via its actions on myeloid cells at the site of inﬂammation [47]. Overall, the potential production
f a broad range of pro-inﬂammatory cytokines by IL-17+ CD8+ T cells indicates these cells may  contribute to pathogenesis via activation
f neighbouring haematopoietic and stromal cells.
.2. Plasticity
Cytokine heterogeneity and plasticity are characteristic features of CD4+ IL-17+ T cells [45,48], and IL-17+ CD8+ T cell plasticity has
een investigated in mouse studies. Adoptive transfer of in vitro generated and sorted IL-17+ CD8+ T cells, IFN-+ CD8+ T cells and IL-17+
FN-+ CD8+ T cells to C3HAhigh mice, which express haemagglutinin as a self antigen, resulted in a persistence of IL-17+ CD8+ T cells
nd IL-17+ IFN-+CD8+T cells but a loss of IFN-+ CD8+ T cells in recipient lungs after 7 days [26]. Adoptive transfer of IL-17-polarised
remelanosome protein-1 speciﬁc CD8+ T cells to mice with melanoma led to a conversion of the IL-17+ CD8+ T cells towards an IFN-+
D8+ T cell phenotype from days 5–11, with a small presence of dual-producing CD8+ T cells [49]. The most signiﬁcant IFN- expression
as observed within transferred IL-17+ CD8+ T cells, indicating plasticity of these cells in vivo. Culture of naive CD8+ T cells from IL-17A-
GFP reporter mice with IL-12 resulted in an IFN-+ cell subset within EGFP+ cells, conﬁrming that IL-17+ IFN-+ CD8+ T cells can derive
rom IL-17+ CD8+ T cells in vivo [50]. A recent study utilising reporter IL-17A-YFP mice investigated the in vivo cytokine proﬁle of CD8+
FP+ T cells 7 and 21 days post-allogeneic stem cell transplant [30]. Cytokine proﬁle heterogeneity with expression of IL-13, IL-22, TNF-,
M-CSF and IFN- and minimal IL-10 expression was observed at day 7, and at 21 days CD8+ YFP+ cells possessed a pro-inﬂammatory
ytokine proﬁle, predominantly co-expressing IFN-, TNF- and GM-CSF.
.3. Cytotoxicity
IL-17+ CD8+ T cells are mostly characterised as non-cytotoxic in mice [23–26,29] and humans [7,10] thus distinguishing these cells
rom IFN-+ CD8+ T cells. However, there are data implicating the cytotoxic function of IL-17+ CD8+ T cells in both mice [32] and humans
5]. Additionally, IL-12-converted mouse IL-17+ IFN-+ CD8+ T cells possessed more cytotoxic activity than IL-17-expressing CD8+ T
ells [50,51] and like IFN-+ CD8+ T cells, possessed anti-tumour functions [50]. Thus, variability in cytotoxicity may  indicate functional
ifferences of IL-17-expressing CD8+ T cells; however it remains to be determined whether and how (lack of) cytotoxic activity contributes
o human inﬂammatory disease.
.4. Pathogenicity
The pathogenicity of IL-17+ CD8+ T cells has been mainly investigated using transgenic mouse models. Using the OT-I transgenic model,
ntigen-speciﬁc IL-17+ CD8+ T cells treated with IL-23 were found to be diabetogenic when adoptively transferred into RIP-mOVA mice.
he pathogenicity was diminished upon treatment with anti-IL-17A and anti-IL-17F antibodies, indicating that IL-17 is essential for disease
evelopment [32]. Furthermore, in EAE mice myelin oligodendrocyte glycoprotein-speciﬁc CD8+ T cells isolated from the lymph nodes
nd central nervous system at the peak of disease were found to express IL-17 ex vivo (after PMA  and ionomycin stimulation). These cells
id not express granzyme B, indicating their potential pathogenicity was  not dependent on a cytotoxic mechanism and may  be related
o pro-inﬂammatory cytokine production [24]. As previously mentioned, healthy individuals carrying the protective R381Q variant in
he IL23R locus had a lower IL-17+ CD8+ T cell frequency in peripheral blood compared to those who did not carry the variant [36]. Since
arriage of this variant (or others in high linkage disequilibrium with R381Q) confers decreased susceptibility to immune mediated diseases
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uch as inﬂammatory bowel disease, ankylosing spondylitis and psoriasis [52–54], this indicates a potential unidentiﬁed role of IL-17+
D8+ T cells in the pathogenesis of these diseases. In the context of psoriatic arthritis, CD8+ IL-17+ T cells frequencies were increased in
he synovial ﬂuid compared to peripheral blood, correlated with several clinical parameters of disease and were associated with erosive
isease, suggesting these cells may  play a role in the pathogenesis of this disease [7].
. Concluding remarks
A growing evidence base indicates the presence of IL-17+ CD8+ T cells at sites of inﬂammation in humans. These cells bear resemblance
o their IL-17+ CD4+ T cell counterparts in terms of phenotypic markers and cytokine co-expression typically associated with Th17 cells.
he exact requirements for differentiation and/or polarisation of IL-17+ CD8+ T cells are less well-deﬁned, particularly in humans. Future
n-depth phenotypic, molecular and functional characterisation of these cells will help determine how IL-17+ CD8+ T cells may  contribute
o human inﬂammatory disease.
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